Baird Financial Group Inc. Sells 2,739 Shares of Guardant Health, Inc. (NASDAQ:GH)

Baird Financial Group Inc. lessened its position in Guardant Health, Inc. (NASDAQ:GHGet Rating) by 16.1% in the second quarter, HoldingsChannel.com reports. The fund owned 14,284 shares of the company’s stock after selling 2,739 shares during the period. Baird Financial Group Inc.’s holdings in Guardant Health were worth $576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Comerica Bank acquired a new stake in shares of Guardant Health during the 1st quarter worth about $612,000. State of New Jersey Common Pension Fund D raised its stake in Guardant Health by 5.5% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 55,377 shares of the company’s stock worth $3,668,000 after purchasing an additional 2,876 shares in the last quarter. Banque Pictet & Cie SA raised its stake in Guardant Health by 13.6% in the 1st quarter. Banque Pictet & Cie SA now owns 118,314 shares of the company’s stock worth $7,837,000 after purchasing an additional 14,124 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Guardant Health by 5.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,834 shares of the company’s stock worth $386,000 after purchasing an additional 318 shares in the last quarter. Finally, Pictet & Cie Europe SA raised its stake in Guardant Health by 23.8% in the 1st quarter. Pictet & Cie Europe SA now owns 8,445 shares of the company’s stock worth $559,000 after purchasing an additional 1,625 shares in the last quarter. Institutional investors own 89.36% of the company’s stock.

Insider Activity at Guardant Health

In other Guardant Health news, insider Kumud Kalia sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $51.87, for a total transaction of $162,093.75. Following the sale, the insider now directly owns 20,135 shares of the company’s stock, valued at approximately $1,044,402.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is currently owned by insiders.

Guardant Health Trading Down 0.5 %

Shares of Guardant Health stock opened at $48.17 on Monday. The firm has a market capitalization of $4.93 billion, a PE ratio of -8.12 and a beta of 0.63. The company has a current ratio of 6.46, a quick ratio of 6.10 and a debt-to-equity ratio of 6.82. The firm’s 50 day moving average is $50.85 and its 200 day moving average is $47.06. Guardant Health, Inc. has a 1 year low of $27.65 and a 1 year high of $111.48.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Piper Sandler cut shares of Guardant Health from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $65.00 to $50.00 in a research note on Tuesday, November 1st. Cowen dropped their price objective on shares of Guardant Health from $110.00 to $83.00 in a research note on Friday, November 4th. JPMorgan Chase & Co. dropped their price objective on shares of Guardant Health from $100.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday. Stephens dropped their price objective on shares of Guardant Health from $99.00 to $90.00 and set an “overweight” rating for the company in a research note on Monday, November 7th. Finally, OTR Global cut shares of Guardant Health to a “positive” rating in a research report on Monday, August 1st. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.60.

About Guardant Health

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Articles

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.